ZambiaTuberculosis profile
Population  2015 16 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5 (2.9–7.7) 31 (18–47)
Mortality (HIV+TB only) 12 (6.9–20) 77 (42–121)
Incidence  (includes HIV+TB) 63 (41–91) 391 (253–558)
Incidence (HIV+TB only) 38 (24–55) 235 (149–339)
Incidence (MDR/RR-TB)** 2.3 (1.4–3.2) 14 (8.6–20)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 2.8 (1.1–4.5) 21 (8.8–33) 24 (9.9–38)
Males 3.2 (1.9–4.5) 36 (25–47) 39 (27–52)
Total 6 (3.9–8.2) 57 (44–71) 63 (41–91)
TB case notifications, 2015  
Total cases notified 41 588
Total new and relapse 36 741
          - % tested with rapid diagnostics at time of diagnosis 100%
          - % with known HIV status 95%
          - % pulmonary 79%
          - % bacteriologically confirmed among pulmonary 49%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 58% (41–90)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.29 (0.16–0.48)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 20 967 60%
          - on antiretroviral therapy 15 897 76%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 500
(990–2 100)
Estimated % of TB cases with MDR/RR-TB 1.1% (0.13–2.1) 18% (11–26)  
% notified tested for rifampicin resistance <1% 9% 695
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 196, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 99, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 85% 37 930
Previously treated cases, excluding relapse, registered in 2014 80% 4 786
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 33% 58
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 66%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 11
Funding source: 9% domestic, 51% international, 40% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data